Celiac disease (CD) is a chronic enteropathy characterized by an autoimmune reaction in the small intestine in genetically-susceptible individuals. Gluten is the required environmental trigger of clinical CD, but the underlying causes of the autoimmune reaction remain unknown. Herein, we apply lipidomics to elucidate the early events preceding clinical CD in a prospective study of children observed from birth until diagnosis of CD and subsequent introduction of a gluten-free diet.
INTRODUCTION
Celiac disease (CD) is a chronic, systemic, autoimmune enteropathy triggered by dietary gluten and related prolamines from rye and barley in genetically-susceptible individuals [1] [2] [3] [4] [5] [6] .
About 90-95% of CD patients express HLA-DQ2 protein, while the remaining (5-10%) express HLA-DQ8 7, 8 . CD is characterized by a wide range of gastro-and extraintestinal symptoms that include diarrhea, weight loss, abdominal distention, malabsorption and iron-deficiency anemia 1, 4, 9 . Serologic tests such as measurement of serum IgA and/or IgG tissue transglutaminase antibodies, IgA endomysial antibodies, deamidated gliadin peptide antibodies (IgG class) are performed for screening and diagnosis of CD. In addition, a biopsy of small intestine is still required in many countries to confirm the diagnosis 2, 4 .
The incidence of CD and other autoimmune diseases such as type 1 diabetes (T1D) have been increasing in children and adults over the past decades 10, 11 . The occurrence of these autoimmune diseases is higher in the Nordic countries 12 than elsewhere, with the highest prevalence of CD occurring in Sweden (29/1000 by the age of 12) and the highest incidence rate of T1D occurs in Finland (64/100000/year for children under 15 years of age) 13, 14 .
Approximately 10% of patients with T1D develop overt CD 15, 16 . On the other hand, people with CD are at-risk for T1D before 20 years of age 17 . These autoimmune diseases share common, predisposing alleles in the class II HLA-region as the DR3-DQ2 and DR4-DQ8 haplotypes [18] [19] [20] [21] .
Recent studies show that, in addition to genetic predisposition and exposure to dietary gluten, other factors such as the composition of the intestinal microbiota, birth delivery mode, infant feeding and the use of antibiotics may also affect the onset of CD 1, 22 . Thus, the early pathogenesis of CD is still poorly understood 4, 23, 24 and the identification of molecular signatures associated with progression to overt CD remains an unmet medical need 3, 4, 24, 25 . The health burden of CD in terms of quality of life, complications, mortality and cost of treatment are considerable, meaning that its prevention has become, in the last decade, an important area of research.
Metabolomics is the study of small (< 1500 Dalton) molecules and their functions in cells, tissues and body fluids 26 . Metabolomic studies in adults diagnosed with active CD 27 identified marked changes in serum and urine metabolic profiles, along with altered intestinal microbiota [28] [29] [30] . Interestingly, a recent, small prospective study suggests an altered early trajectory of the gut microbiome (4 and 6 months of age) in children who later progressed to CD 31 . Given the characteristic metabolic abnormalities observed in clinical CD, we investigate here whether distinct lipidomic signatures exist prior to overt CD. We analyzed molecular lipids in plasma by lipidomics approach in a prospective cohort of children, observed from birth until clinical CD.
MATERIALS AND METHODS

Study design and protocol
The children included in the present study are from the DIPP cohort, which is an ongoing prospective study initiated in 1994. In the DIPP study, parents of newborn infants at the university hospitals of Turku, Tampere and Oulu in Finland are asked for permission to screen the child for HLA alleles conferring risk of T1D, using umbilical cord blood. Families of children identified as having an increased HLA-conferred risk for T1D are invited to join the study. Our analysis included children born at Tampere University Hospital between August 1999 and September 2005. During that period, 23,839 children were screened at birth for increased risk of T1D, and 2,642 eligible children were enrolled in the follow-up and had at least two visits to the study clinic. These children carry the high-risk HLA DQB1*02/*03:02 genotype or the moderate-risk HLA-DQB1*03:02/x genotype (x ≠ DQB1*02, 03:01, or 06:02). More than 1,200 of these children took part in the DIPP-CD study. The DIPP study in Tampere followed the children at regular intervals at the ages of 3, 6, 12, 18, and 24 months and subsequently at intervals of 12 months for children without T1D-related autoantibodies. At each visit, the families were interviewed for diet, infections, growth, important family-related issues and the children gave a non-fasting venous blood sample. The children were followed for four CD-related antibodies: anti-tissue transglutaminase (anti-tTG), anti-endomysium (EMA), antigliadin (AgA-IgG and AgA-IgA) and anti-reticulin (ARA) antibodies, and for T1D-associated autoantibodies: islet cell antibodies (ICA). If a sample was positive for ICA, then insulin autoantibodies (IAA), antibodies against tyrosine phosphatase-like protein (IA-2A) and glutamate decarboxylase (GADA) were measured from all samples taken from that child. From the beginning of 2003, all samples were measured for the four T1D-associated autoantibodies.
All children participating in this study were of Caucasian origin. IgA deficiency was excluded. One of the mothers had CD. The children in the CD follow-up cohort were annually screened for anti-tTG antibodies (tTGA) using a commercial kit (Celikey Pharmacia Diagnostics, Freiburg, Germany). If any given child's sample was found to be positive for tTGA, all of that child's previous and following samples were analyzed for the entire set of CD-related antibodies. A duodenal biopsy was recommended for all tTGApositive children. If the biopsy was consistent with the ESPGHAN criteria of 1990, a glutenfree diet (GFD) was recommended. Three of the CD cases were also diagnosed with T1D, one just before the diagnosis of CD and the other ones after the diagnoses of CD (62 and 76 months later).
We randomly selected 23 children (12 males and 11 females) with biopsy-proven CD (progressors) and a control for each progressor matched for age, gender, and with the same risk HLA alleles, and living in the Tampere region throughout the whole follow-up period.
None of the controls were diagnosed with T1D. The original HLA screening for CD patients and suitable controls was also completed to a "full house" DQ typing to verify the presence of DQA1*05 in selected DQB1*02 positive children 32 . These clinical and genetic annotations of the participants are given in Table 1 . Furthermore, the children were exclusively breastfed until 1.6 months (median) and some were exclusively breastfed up to 8.0 months of age. The first exposure to gluten in this study was at a median age of 6.0 months. The children (case and control) had comparable (nominal, non-significant difference) energy (KJ), fat (g), carbohydrate (oat, rye, wheat), and gluten intakes (see Supplementary
Figures S1 & S2).
Maternal total diet during pregnancy and lactation was ascertained by a validated food frequency questionnaire 33 . Infant feeding was studied by structured questionnaires, which families filled in at home, and which were checked during the clinic visits. The child's diet was assessed with 3-day food records at 3, 6, and 12 months followed by 2, 3, 4 and 6 years of age visits. The food records were posted before the study visit or given at the previous visit with detailed, written instructions. The families and daycare personnel were instructed to write down all the foods, drinks and dietary supplements the child consumed, with the amounts and brand names during one weekend day and two week-days. The study nurses checked the records at the study visit and helped to estimate any incomplete portion sizes with a picture booklet. The collection, processing and calculation of food consumption data has been described previously in detail 34 
Analysis of molecular lipids
A total of 233 plasma samples were randomized and extracted using a modified version of the Folch procedure 35 . Promptly after extraction, 10 µL of 0.9% NaCl and 120 µL of 
Statistical methods
The samples from CD progressors and controls were divided into different age groups based on time difference between the date of the sample withdrawn and date of birth of the subject (Supplementary Figure S7) . If more than two samples from the same case matched a time interval, the closest was taken. The data was then log2 transformed.
Homogeneity of the samples were assessed by principal component analysis (PCA) 37 and no outliers were detected.
The R software (http://www.r-project.org) was used for data analysis and visualization. and standardized in this study ( Table 1) , other factors such as subject-wise variability can be modelled and derived using LME models. The LME models were restricted to constant terms with the fixed effect being CD progression/non-progression (control), age, gender and the random effect being subject-wise variation in comparison to the group-specific mean level. Fitted LME models showed, gender difference has nominal effect on the metabolite intensities. The fully parametrized model was compared to a null model using analysis of variance (ANOVA) 45 ('aov()' as deployed in the 'stats' package). The lipid profiles that changed significantly (p < 0.05) were subjected to False Discovery Rates (FDR) adjustment using p-adjust(). Lipid profiles with FDR < 0.05 were listed.
Next, post-hoc analysis using Tukey's test for Honest Significant Difference (HSD) was performed on these selected lipids to see, if at all, they are changing between progressors and non-progressors at a particular age. A list of differentially altered lipids that also showed HSD (p-values < 0.05) between CD progressor and healthy control at a particular age was marked. These lipids were considered for further analysis.
HSD was performed using 'TukeyHSD()' function deployed in the 'stats' package. Loess regression was performed using 'loess()' deployed in the 'stats' package. Spearman's correlation coefficient was calculated using 'rcorr()' function implemented in 'Hmisc' package. 'Heatmap.2()' and 'boxplot()' was used for data visualization.
RESULTS
Global plasma lipidome in progression to celiac disease
The complete lipidomics dataset was first explored using multivariate analysis. Among other factors affecting the lipidome, age was found to be a major confounding factor (Supplementary Figure S8) . (Figure 1b) .
Differences between cases and controls were observed already by 3 months of age, i.e., before the introduction of gluten to the diet (Figure 1c) . TGs, PCs and CEs were mostly affected (RC (± 0.05) and VIP 41 scores > 1) at this age (Figure 1d) . The cord plasma lipidome clustered distinctly from other age groups (Supplementary Figure S9) . However, no significant differences (HSD, p-values > 0.05) in the cord plasma lipids were observed between CD progressors and their matched healthy controls (Figure 2a) .
Molecular lipids in progression to overt CD
Longitudinal analysis of lipidomic profiles at the individual lipid level identified 80 molecular lipids (from a total of 239) occurring at significantly-different levels over time between CD progressors and healthy controls (FDR-adjusted p-values < 0.05) (Figure 2a) .
The level and direction of regulation of TGs depends on their chemical structure. There was an association between the fold change in TGs (CD progressors vs. healthy controls) and the TG double bond count as well as the TG carbon number (Figure 2b-e Figures 2b and 2d) . Interestingly, at a later age, these TGs with lower double bond and carbon numbers were down-regulated with (R= 0.79; p-values =0.08) and
(R= 0.44; p-values = 0.0002), respectively (Figure 2c and Figure 2e) . Notably, four such TGs were elevated in progressors at 3 months of age (HSD, p-values < 0.05). No significant changes were detected for dietary TGs; such as those containing polyunsaturated fatty acids (PUFAs). Representative longitudinal profiles for selected significantly-altered lipids between CD progressors and healthy controls are shown in Figure 3 .
Impact of tissue transglutaminase antibodies on lipidomic profiles
Tissue transglutaminase (tTG) is a multifunctional, calcium-dependent enzyme (EC 2.3.2.13) that plays an important role in the pathogenesis of CD. Antibodies produced against tTG, anti-tissue transglutaminase antibodies (tTGA), are used as serological markers with high sensitivity (99%) and reasonable specificity (> 90%) for the diagnosis of CD 2, 46, 47 .
We examined tTGA titers in 23 CD progressors at two different stages, (1) immediately after the seroconversion for tTGA, and (2) 6-12 months after both seroconversion and introduction of GFD. First, we identified at least seven 'essential' TGs, i.e., TGs of dietary origin, in our lipidomics dataset. The identities of these TGs were validated using external sources including both the Human Metabolome Database (HMDB) 48 and FooDB.ca (http://foodb.ca/). Spearman correlation analysis was then performed between the levels of selected TGs (34 significantly-changed, nonessential and seven non-significantly changed essential TGs) and PCs (18 PCs + 2 LPCs) with measured tTGA levels at these stages. The aim was to determine whether the systemic levels of TGs and PCs are associated with antibody titers during CD progression. A positive correlation (Spearman's rank coefficient, d avg = +0.174; minimum p-value = 0.01) was found between the TG and tTGA levels after seroconversion (Figure 4a) . However, a negative correlation was found at a later age, where the levels of tTGA decreased considerably (d avg = -0.163; minimum p-value = 0.05). In addition, at least 16 PCs were negatively correlated at these two different timepoints (d avg = -0.02 and -0.13; minimum p-values = 0.01 and 0.02 respectively) (Figure 4b) .
It is known that GFD decreases tTGA levels in CD patients 49 , whilst it also improves the total cholesterol levels and high density lipoprotein (HDL) profiles without any significant increase in low density lipoproteins (LDL) 50 .
Impact of gluten on molecular lipids
We then divided the cohort into three subgroups, (1) before the introduction of gluten in the diet (3 months) (2) after the introduction of gluten (12-36 months), and (3) after the introduction of GFD (72 months, CD progressors only).
We observed a decrease in total essential TG level in the plasma of the CD progressors after gluten intake (Figure 5a, Supplementary Figure S10a) . Introduction of GFD reversed this trend, but the changes were not significant (ANOVA, p-values > 0.05) (Figure 5a, Figure   5e ). On the other hand, levels of nonessential endogenous TGs were decreased (ANOVA, p-values = 0.004) in the plasma of the CD progressors after commencement of gluten intake and even after the diagnosis of clinical CD and introduction of GFD (p-values = 0.001). The trend in the change of nonessential TGs was also observed in healthy controls (p-values = 0.007 and 0.01, respectively) (Figure 5b, Figure 5e and Supplementary Figure S10b) .
Moreover, there was a difference (p-values < 0.05) in nonessential TGs levels between CD progressors and healthy controls as predicted by Tukey's test for HSD (Figure 2a) . These findings suggest that dysregulation of lipid metabolism might occur at an early stage of CD progression, even before the introduction of gluten in the diet.
PCs were elevated both in the progressors (p < 0.004) and controls (p < 0.007) after the commencement of gluten intake (Figure 5c, Figure 5e and Supplementary Figure S10c) .
PCs are the major class of phospholipids that form the cellular constituents required for the assembly of biological membranes. In contrast to healthy controls, no significant differences in SM level were observed in the CD progressors after commencement of gluten intake. A difference in the plasma SM level was observed only at a later age, after the introduction of GFD (Figure 5d, Figure 5e and Supplementary Figure S10d) .
DISCUSSION
We identified systematic differences in plasma lipidomes between children who progressed to clinical CD as compared to children who remained healthy during the follow-up. These differences were observed before the exposure to gluten in the diet and before the first signs of CD-associated autoimmunity. The dysregulation of the plasma lipidome in CD progressors is dominated by complex lipids such as PLs, TGs and CEs. As there is no evidence of gut damage in any studies performed so far in individuals who are autoantibody-negative for tTGA, it is unlikely that these systematic differences are caused by gluten from breast milk, or other sources in the infants' diet causing damage to the gut immediately after birth. An earlier lipidomics study in the PreventCD cohort did not find significant differences between CD progressors and matched controls at 4 months of age 51 .
However, that study used a targeted analysis focusing on a subset of phospholipids and acyl-carnitines, and did not measure TGs and CEs, where the major changes were found to have occurred in our study.
In this study, several nonessential TGs were up-regulated in CD progressors as early as 3 months of age, i.e., before the first introduction of gluten to the diet. However, no significant changes in dietary TGs were found at this age. Lipid malabsorption is believed to be a side effect of flattened villi in the small intestine 27, 29 . However, our data suggest that lipid-related abnormalities are not caused by CD-related villous atrophy in the gut.
One plausible explanation that arises is that lipid malabsorption can lead to a reduction in cholesterol-transporting lipoproteins, and secretion of apolipoprotein (Apo)-A1 52, 53 . A decrease in the level of CEs in CD progressors during the first 3 months after birth supports this explanation. Moreover, CEs were up-regulated at a later age after the introduction of GFD (Figure 2a and Figure 3a) . Lipid malabsorption may thus occur at a very early age in CD progressors and, therefore, de novo lipogenesis 54 , as reflected by increased levels of TGs with low carbon number and double bond content, may be necessarily increased in order to compensate for said compromised lipid uptake. Interestingly, this phenomenon was not observed at birth (i.e., in the cord blood data), thus suggesting that the observed lipid dysregulation is not an inborn phenomenon.
Furthermore, an inverse relationship between endogenous TGs and tTGA titer after seroconversion and introduction of GFD in the CD progressors also reaffirms the involvement of TGs and other phospholipids (PCs) in CD progression. Indeed, there was an increase in cholesterol levels after the introduction of GFD and there was a decrease in tTGA titers, in agreement with previous studies 49, 50 . Presumably, these lipids may play a protective role against seroconversion to tTGA positivity and CD progression.
We found, in earlier studies, that T1D is preceded by dysregulation of lipid metabolism [55] [56] [57] . The key findings from these studies were that islet autoimmunity and overt T1D are preceded by diminished phospholipid and TG levels. While there are some similarities at an early age in phospholipid profiles in T1D and, as shown in the current study, CD progressors, no such similarities exist for TGs. The increase of TGs with low carbon number and double bond count does appear to be specific to CD progression. These TGs are associated, in adults, with elevated liver fat in non-alcoholic fatty liver disease (NAFLD) 58, 59 , reflecting increased de novo lipogenesis and adipose tissue lipolysis. In fact, CD patients have, interestingly, been found to be at increased risk of NAFLD 60 . Our findings may thus offer an explanation for this association.
The main limitation of this study is the relatively small number of children included.
However, this is mitigated by the longitudinal study setting, with five prospective samples, from birth until after the introduction of GFD, on average, from each child. The subjects of our study were well-matched with their controls for genetic and environmental factors.
In summary, our study suggests that lipid-related abnormalities in CD progressors demonstrably occur prior to the first introduction of gluten to the diet. These changes may be related to impaired lipid absorption as well as de novo lipogenesis, with both of these being part of the host response. Our findings may, therefore, have important clinical implications for the detection of subjects at-risk for CD as well as for the understanding of early pathogenesis of CD.
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